AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held the top spot, the total impressions dipped by 2 million from when Sanofi ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety ProfileHONG KONG, Apr 9, 2025 - (ACN Newswire) - SinoMab BioScience ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Stock analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for Sanofi in a report released on ...

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ...